[go: up one dir, main page]

MX2018005233A - Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer. - Google Patents

Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.

Info

Publication number
MX2018005233A
MX2018005233A MX2018005233A MX2018005233A MX2018005233A MX 2018005233 A MX2018005233 A MX 2018005233A MX 2018005233 A MX2018005233 A MX 2018005233A MX 2018005233 A MX2018005233 A MX 2018005233A MX 2018005233 A MX2018005233 A MX 2018005233A
Authority
MX
Mexico
Prior art keywords
inhibitor
cancer
treatment
combination
bcl
Prior art date
Application number
MX2018005233A
Other languages
English (en)
Other versions
MX379621B (es
Inventor
Merchant Mark
Sampath Deepak
Han Lina
Yurievna Konopleva Marina
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2018005233A publication Critical patent/MX2018005233A/es
Publication of MX379621B publication Critical patent/MX379621B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una terapia de combinación que implica un inhibidor de Bcl-2 selectivo y un inhibidor de MEK para el tratamiento de un paciente en necesidad de esta terapia. El paciente en necesidad de terapia de combinación está padeciendo de cáncer, tal como leucemia mieloide aguda.
MX2018005233A 2015-11-03 2016-11-03 Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer MX379621B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250231P 2015-11-03 2015-11-03
US201562263082P 2015-12-04 2015-12-04
PCT/US2016/060271 WO2017079399A1 (en) 2015-11-03 2016-11-03 Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2018005233A true MX2018005233A (es) 2019-04-29
MX379621B MX379621B (es) 2025-03-11

Family

ID=57471995

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005233A MX379621B (es) 2015-11-03 2016-11-03 Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer

Country Status (12)

Country Link
US (2) US10959993B2 (es)
EP (1) EP3370775B1 (es)
JP (1) JP6724136B2 (es)
KR (1) KR102124715B1 (es)
CN (1) CN108601839B (es)
AU (1) AU2016349279A1 (es)
BR (1) BR112018008882A8 (es)
CA (1) CA3001880C (es)
IL (1) IL258741B (es)
MA (1) MA43170A (es)
MX (1) MX379621B (es)
WO (1) WO2017079399A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1212240A1 (en) * 2012-09-07 2016-06-10 吉宁特有限公司 Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
US20190328729A1 (en) 2018-04-26 2019-10-31 Emory University Uses of Bcl-2 Antagonists for Treating Cancer and Diagnostics Related Thereto
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
TW202023568A (zh) * 2018-07-30 2020-07-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法
EP4268822A3 (en) * 2018-10-16 2024-01-03 The Johns Hopkins University Compositions for treating vascular ehlers danlos syndrome
TWI848030B (zh) * 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
WO2020160157A1 (en) * 2019-01-30 2020-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Detection of bcl-2 family heterodimer complexes and use thereof
US20220136068A1 (en) * 2019-03-06 2022-05-05 The Regents Of The University Of Colorado, A Body Corporate Methods of detecting and treating venetoclax-resistant acute myeloid leukemia
WO2020223351A1 (en) * 2019-04-29 2020-11-05 Immunogen, Inc. Therapeutic combinations comprising anti-cd123 immunoconjugates
WO2020247275A2 (en) * 2019-06-03 2020-12-10 Sanford Burnham Prebys Medical Discovery Institute Uses of synthetic lethal partners for treatment of cancer
CN115135325A (zh) * 2019-12-20 2022-09-30 里科瑞尔姆Ip控股有限责任公司 组合
EP4183397A4 (en) * 2020-07-17 2024-03-27 Delta-Fly Pharma, Inc. NEW THERAPY AND NEW THERAPEUTIC FOR BLOOD CANCER
CN117257959B (zh) * 2022-12-21 2025-07-29 宁波大学附属人民医院 一种包含Bcl-2抑制剂和STAT抑制剂的药物组合物
CN116270642B (zh) * 2022-12-27 2025-03-21 中国科学技术大学 汉防己甲素在缓解继发性噬血细胞综合症药物中的应用
WO2025043183A1 (en) * 2023-08-23 2025-02-27 Eigen Therapeutics Inc. Methods and compositions for treating hematological cancers

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
CA2722992A1 (en) * 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
IL225340A (en) 2010-10-29 2017-05-29 Abbvie Inc Solid dispersions containing cell mortality
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
US20120129853A1 (en) 2010-11-23 2012-05-24 Abbott Laboratories Methods of treatment using selective bcl-2 inhibitors
SI2643322T1 (en) 2010-11-23 2018-01-31 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
RU2607944C2 (ru) * 2011-08-31 2017-01-11 Новартис Аг Синергические композиции ингибиторов pi3k и мек
KR20150038068A (ko) 2012-08-17 2015-04-08 에프. 호프만-라 로슈 아게 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
HK1212240A1 (en) 2012-09-07 2016-06-10 吉宁特有限公司 Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
WO2015051252A1 (en) 2013-10-03 2015-04-09 Duke University Compositions and methods for treating cancer with jak2 activity

Also Published As

Publication number Publication date
CN108601839B (zh) 2021-10-26
US20210169865A1 (en) 2021-06-10
EP3370775B1 (en) 2023-04-19
BR112018008882A2 (pt) 2018-11-06
US10959993B2 (en) 2021-03-30
MX379621B (es) 2025-03-11
BR112018008882A8 (pt) 2019-02-26
MA43170A (fr) 2018-09-12
CA3001880A1 (en) 2017-05-11
JP6724136B2 (ja) 2020-07-15
KR102124715B1 (ko) 2020-06-18
IL258741B (en) 2021-08-31
IL258741A (en) 2018-06-28
HK1259545A1 (en) 2019-11-29
CA3001880C (en) 2021-08-17
EP3370775A1 (en) 2018-09-12
CN108601839A (zh) 2018-09-28
US20180303815A1 (en) 2018-10-25
WO2017079399A1 (en) 2017-05-11
KR20180054852A (ko) 2018-05-24
AU2016349279A1 (en) 2018-05-10
JP2018534298A (ja) 2018-11-22

Similar Documents

Publication Publication Date Title
MX2018005233A (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
MX2017008844A (es) Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
MX394062B (es) Métodos para el tratamiento del cáncer ovárico.
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
MX382902B (es) Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
GEAP202014670A (en) Agents, Uses and Methods for the Treatment of Synucleinopathy
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
EA201791736A1 (ru) Комбинированная терапия для лечения рака
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
MX2015011753A (es) Metodos para tratar cancer de vegija.
MX387283B (es) Tratamiento del cancer con tg02.
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
EA201991818A1 (ru) Лечение рака
PE20180454A1 (es) Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2
MX2019009304A (es) Tratamiento para el cancer.
PH12017501879A1 (en) Methods for treating cancer
TW201613587A (en) Medical treatments based on anamorelin
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.